Association between Plasma Levels of Plasminogen Activator Inhibitor-1 and Colorectal Neoplasms
0
조회
0
다운로드
0
인용
0
참고문헌
초록
Background/Aims: Plasminogen activator inhibitor-1 (PAI-1) is important for tumor growth, Invasion, and metastasis. In this study, we investigated the relationship between plasma levels of PAI-1 and colorectal adenomas. Methods:We reviewed the medical records of 3,136 subjects who underwent colonoscopy as a screening exam. The subjects were classified into a case group with adenomas (n=990)and a control group (n=2,146). Plasma PAI-1 levels were categorized into three groups based on tertile. Results: The plasma levels of PAI-1 were significantly higher in adenoma cases than in controls (p=0.023). The prevalence of colorectal adenomas increased significantly with increasing levels of PAI-1 (p=0.038). In the adenoma group, advanced pathologic features, size, and number of adenomas did not differ among the three groups based on tertiles for plasma PAI-1 levels. Using multivariate analysis, we found that plasma level of PAI-1 was not associated with the risk of colorectal adenomas (p=0.675). Adjusted odds ratios for colorectal adenomas according to increasing plasma levels of PAI-1 were 0.980 (95% confidence interval [CI], 0.768 to 1.251) for the second-highest plasma level and 1.091 (95% CI, 0.898 to 1.326) for the highest level, compared with the lowest levels. Conclusions: These results suggest that elevated plasma PAI-1 levels are not associated with the risk of colorectal neoplasms.
Abstract
Background/Aims: Plasminogen activator inhibitor-1 (PAI-1) is important for tumor growth, Invasion, and metastasis. In this study, we investigated the relationship between plasma levels of PAI-1 and colorectal adenomas. Methods:We reviewed the medical records of 3,136 subjects who underwent colonoscopy as a screening exam. The subjects were classified into a case group with adenomas (n=990)and a control group (n=2,146). Plasma PAI-1 levels were categorized into three groups based on tertile. Results: The plasma levels of PAI-1 were significantly higher in adenoma cases than in controls (p=0.023). The prevalence of colorectal adenomas increased significantly with increasing levels of PAI-1 (p=0.038). In the adenoma group, advanced pathologic features, size, and number of adenomas did not differ among the three groups based on tertiles for plasma PAI-1 levels. Using multivariate analysis, we found that plasma level of PAI-1 was not associated with the risk of colorectal adenomas (p=0.675). Adjusted odds ratios for colorectal adenomas according to increasing plasma levels of PAI-1 were 0.980 (95% confidence interval [CI], 0.768 to 1.251) for the second-highest plasma level and 1.091 (95% CI, 0.898 to 1.326) for the highest level, compared with the lowest levels. Conclusions: These results suggest that elevated plasma PAI-1 levels are not associated with the risk of colorectal neoplasms.
참고문헌 (21)
- McMahon B, "The plasminogen activator system and cancer", Pathophysiol Haemost Thromb, 36, pp.184~194 (2008)
- Bajou K, "Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization", Nat Med, 4, pp.923~928 (1998)
- Sier CF, "Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis", Gastroenterology, 101, pp.1522~1528 (1991)
- Papadopoulou S, "Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas", Tumour Biol, 23, pp.170~178 (2002)
- Nilsson L, "Unsaturated fatty acids increase plasminogen activator inhibitor-1 expression in endothelial cells", Arterioscler Thromb Vasc Biol, 18, pp.1679~1685 (1998)
- Nilsson L, "VLDL activation of plasminogen activator inhibitor-1 (PAI-1) expression: involvement of the VLDL receptor", J Lipid Res, 40, pp.913~919 (1999)
- Liu CS, "Central obesity and atherogenic dyslipidemia in metabolic syndrome are associated with increased risk for colorectal adenoma in a Chinese population", BMC Gastroenterol, 10, pp.51~ (2010)
- Tabuchi M, "Hypertriglyceridemia is positively correlated with the development of colorectal tubular adenoma in Japanese men", World J Gastroenterol, 12, pp.1261~1264 (2006)
- Baker EA, "The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology", Eur J Cancer, 39, pp.981~988 (2003)
- de Bruin PA, "Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas", Cancer Res, 47, pp.4654~4657 (1987)
- Protiva P, "Alterations in plasminogen activation correlate with epithelial cell dysplasia grading in colorectal adenomas", Br J Cancer, 77, pp.297~304 (1998)
- Stefansson S, "Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling", Curr Pharm Des, 9, pp.1545~1564 (2003)
- Andreasen PA, "PAI-1: a potential therapeutic target in cancer", Curr Drug Targets, 8, pp.1030~1041 (2007)
- Binder BR, "The plasminogen activator inhibitor “paradox” in cancer", Immunol Lett, 118, pp.116~124 (2008)
- Duffy MJ, "The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer", Clin Biochem, 37, pp.541~548 (2004)
- Seetoo DQ, "Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer", J Surg Oncol, 82, pp.184~193 (2003)
- Forsti A, "Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer", Ann Oncol, 18, pp.1990~1994 (2007)
- Loktionov A, "Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis", Cancer Lett, 189, pp.189~196 (2003)
- Langenskiold M, "Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer", Tumour Biol, 30, pp.210~220 (2009)
- Nielsen HJ, "Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer", BMJ, 316, pp.829~830 (1998)
- Mutoh M, "Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice", Carcinogenesis, 29, pp.824~829 (2008)